checkAd
    Startseite > Aktien > Compass Therapeutics > Nachrichten
    Compass Therapeutics Aktie
    1,2900
     
    USD
    -1,53 %
    -0,0200 USD
    Letzter Kurs 18:44:59 Nasdaq
    1,2700
     
    USD
    100 STK
    Geldkurs 18:45:15
    1,3000
     
    USD
    400 STK
    Briefkurs 18:45:15
    ISIN: US20454B1044 · WKN: A2QF3P · SYM: CMPX · USA

    Neueste Nachrichten

    Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
    30.05.24 · globenewswire · Compass Therapeutics
    Compass Therapeutics Announces CEO Transition
    28.05.24 · globenewswire · Compass Therapeutics
    Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Mee
    23.05.24 · globenewswire · Compass Therapeutics
    Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
    14.05.24 · globenewswire · Compass Therapeutics
    Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
    13.05.24 · globenewswire · Compass Therapeutics
    Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
    25.04.24 · globenewswire · Compass Therapeutics
    Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
    16.04.24 · globenewswire · Compass Therapeutics
    Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
    12.04.24 · globenewswire · Compass Therapeutics
    Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
    10.04.24 · globenewswire · Compass Therapeutics
    Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
    09.04.24 · globenewswire · Compass Therapeutics
    Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
    21.03.24 · globenewswire · Compass Therapeutics
    Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
    29.02.24 · globenewswire · Compass Therapeutics